Table 3 Outcome at 5 years according to PTEN/RAS genotype in the NOTCH1/FBXW7 subgroups

From: Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial

NOTCH1/FBXW7 subgroup

PTEN/RAS genotype

RFS

OS

  

Events/n

% (95% CI)

Pa

Events/n

% (95% CI)

Pa

NOTCH1±FBXW7Double

PTEN WT

2/32

94% (77–98%)

0.57

0/32

100%

N/Ab

 

PTEN ABN

0/5

100%

 

0/5

100%

 
 

PTEN/RAS WT

2/28

93% (74–98%)

0.42

0/28

100%

N/Ab

 

PTEN/RAS ABN

0/9

100%

 

0/9

100%

 

NOTCH1 Single FBXW7 WT

PTEN WT

7/41

83% (67–93%)

0.68

4/41

90% (76–96%)

0.24

 

PTEN ABN

3/14

79% (47–93%)

 

3/14

79% (47–93%)

 
 

PTEN/RAS WT

7/38

81% (64–91%)

0.98

4/38

89% (74–96%)

0.44

 

PTEN/RAS ABN

3/17

82% (55–94%)

 

3/17

82% (55–94%)

 

NOTCH1 WT FBXW7 WT

PTEN WT

5/36

85% (68–94%)

0.82

6/36

83% (67–92%)

0.60

 

PTEN ABN

3/13

83% (48–96%)

 

3/13

77% (47–93%)

 
 

PTEN/RAS WT

5/33

87% (69–95%)

0.49

5/33

85% (67–93%)

0.39

 

PTEN/RAS ABN

4/16

80% (50–93%)

 

4/16

75% (46–90%)

 
  1. Abbreviations: ABN, abnormal; CI, confidence interval; OS, overall survival; RFS, relapse-free survival; WT, wild type.
  2. aP-values: Log-rank test.
  3. bNot applicable as no deaths reported.